Purpose: To investigate the absorption of moxifloxacin into human aqueous humor after administration of moxifloxacin hydrochloride ophthalmic solution, 0.5% as base.
E ndophthalmitis is a potentially devastating intraocular infection that occurs after cataract surgery at a minimum incidence of 0.08%. 1, 2 In most cases that occur sporadically, the responsible bacteria are the same species that normally colonize the patient's ocular surface and adnexa. 3 Therefore, most preventive treatments focus on eradicating bacterial flora on the superficial eye tissues before beginning intraocular surgery. 4 Some ophthalmologists advocate beginning topical antibiotics several days preoperatively, while others use topical antibiotics immediately prior to surgery.
While some surgeons use subconjunctival injections, antibiotics in the infusion fluid, or intracameral antibiotics, the topical route has the advantages of ease of use, decreased risk of resistance, fewer complications, and fewer systemic side effects. However, to be effective, the topical antibiotic should penetrate into tissues, act rapidly, and achieve a high therapeutic concentration in the anterior chamber relative to the minimum inhibitory concentrations (MICs) of those organisms that usually cause endophthalmitis. 5 Interest has developed in using moxifloxacin topically to prevent endophthalmitis. Data from a study in pigmented rabbits using a 0.3% formulation of moxifloxacin indicate that moxifloxacin is well absorbed into the eye. 6 The concentrations achieved in the aqueous humor and anterior tissues were higher than those of ofloxacin, another fluoroquinolone included in the same study, which has been considered to be well absorbed when used topically on the eye. [7] [8] [9] The objective of this study was to determine the concentrations of moxifloxacin in human aqueous humor after 2 topical regimens of moxifloxacin hydrochloride ophthalmic solution, 0.5% as base (Vigamox Ò , Alcon Laboratories, Inc., Fort Worth, TX).
MATERIALS AND METHODS
The study protocol was reviewed and approved by an institutional review board. Written informed consent was obtained from each patient prior to enrollment in the study.
This study was an open-label pharmacokinetic trial conducted at 4 U.S. centers. Sixty-one adults who required cataract surgery in one eye were enrolled. To be eligible for participation, patients were required to have visual acuity 20/40 or better (as measured by a potential acuity meter) in the eye scheduled for surgery, and vision correctable to 0.6 logMAR or better in the nonsurgical eye. No patients with a medical or ophthalmic condition that would preclude safe participation or that would interfere with the study outcome were enrolled. Also, patients were excluded from participation if they had nasolacrimal drainage system malfunction, anterior chamber disorder, history or evidence of significant ocular disease, and infection or inflammation of the eye undergoing surgery. Use of other topical ocular drops was prohibited.
Eligible patients were randomly assigned to 2 treatment regimens: group 1 received 1 drop of moxifloxacin ophthalmic solution 0.5% every 15 minutes in the operative eye for 4 doses before surgery and group 2 received 1 drop in the operative eye 4 times per day on the day before surgery plus the same regimen as group 1 before surgery. The maximum amount of topical moxifloxacin received was 8 drops given over 2 days (group 2).
Patients in each treatment group were randomly assigned to undergo aqueous sampling at only one of the following sampling times: 0.25, 0.50, 1, 2, or 3 hours following the last dose. Surgery was scheduled to ensure that aqueous humor samples were collected within 2 minutes of the 0.25-, 0.5-, and 1-hour sampling times and within 5 minutes of the 2-and 3-hour sampling times. The collection of samples at discrete time points allowed for an estimation of pharmacokinetic parameters. Immediately after the anterior chamber was entered, the surgeon used a tuberculin syringe to collect a target volume of 0.15 mL of aqueous humor. Samples were frozen within 1 hour of collection and were stored below 220°C until analysis.
Moxifloxacin concentrations in the human aqueous humor sample were determined using a HPLC-tandem mass spectrometry method. The method was validated for accuracy, precision and stability in accordance with FDA guidelines. In this procedure, 50 mL of human aqueous humor was spiked with tetradeuterated moxifloxacin internal standard. The samples were prepared using reversed-phase, solid-phase extraction cartridges. HPLC was performed on a reversed-phase C8 column. The column effluent was subjected to positive-ion electrospray ionization, and the protonated molecular ions of moxifloxacin and internal standard underwent collisional fragmentation to give characteristic product ions using argon as target gas. Quantification of moxifloxacin was based on a duplicate 9-point calibration curve. All analyses included duplicate quality control (QC) samples at low, mid, and high concentrations relative to the calibration curve. Run acceptance was based on performance of the calibration standards and QC samples.
The primary pharmacokinetic parameters determined were the maximum mean concentration (C max ), time to C max (T max ), and the area under the aqueous concentration-time curve (AUC 0-3h ). The AUC 0-3h and 95% confidence limits were calculated using the linear trapezoidal method for sparse sampling data as described by Nedelman et al. 10 The mean concentrations for all replicates at a given time point were used for AUC calculation, and the variability across all time points allowed estimation of the standard deviation of the AUC. Statistical analyses were performed using SAS, Version 8e.
RESULTS
Sixty-one patients were enrolled into the 2 treatment groups (group 1, n = 30; group 2, n = 31). Aqueous humor samples were obtained from all but one patient, providing 30 samples per group. Table 1 presents the patient demographics.
The mean concentrations and ranges of moxifloxacin in aqueous humor are presented by time after dosing and by dose group in Table 2 . The data for both groups are also graphically presented in Figure 1 . The mean aqueous humor pharmacokinetic parameters are presented in Table 3 . Moxifloxacin was absorbed into the aqueous humor, achieving mean concentrations in excess of 1 mg/mL within 15 minutes. The mean C max for group 2 was 1.74 6 0.66 mg/mL and that for group 1 was 1.50 6 0.75 mg/mL. The difference in C max between the groups was not statistically significant (P = 0.40). The same trend was observed in the mean aqueous humor AUC 0-3h , with the values for group 2 of 4.41 6 0.48 mgÁh/mL greater than group 1 at 3.16 6 0.29 mgÁh/mL. This difference was statistically significant (P = 0.04). The highest mean concentrations were reached at 0.5 hour for group 1 and at 1 to 2 hours for group 2.
DISCUSSION
Moxifloxacin is a fourth-generation fluoroquinolone recently approved for topical ocular use. Although moxifloxacin ophthalmic solution has been approved for the treatment of bacterial conjunctivitis, the fluoroquinolones as a class have been used extensively perioperatively to help prevent endophthalmitis. With fluoroquinolones, this approach can be effective against intraocular pathogens if the drug is well absorbed and achieves concentrations in the tissues and aqueous humor that are high relative to the MICs for ocular pathogens. Hence, the combination of potency and ocular absorption is key to successful prevention.
The bactericidal activities of the fluoroquinolone antibiotics are concentration dependent. The ratio C max :MIC is one appropriate parameter to predict successful bacteriologic response to fluoroquinolone. 11, 12 The aqueous humor concentrations of moxifloxacin determined in this study were compared with the most recent data reported on the MICs of clinical endophthalmitis isolates. Mather et al 13 found that the median MICs for susceptible Staphylococcus aureus and Staphylococcus epidermidis isolates were 0.06 mg/mL and 0.05 mg/mL, respectively. Based on the results of this study, the aqueous C max :MIC ratios following the topical presurgical regimens are approximately 25 to 30 for the S. aureus isolates and 30 to 35 for the S. epidermidis isolates. Depending on the microorganism, antibiotics are usually bactericidal at concentrations approximately 2 to 10 times their MICs. Therefore, at the ratios demonstrated in this study, moxifloxacin should not only inhibit growth but should also be bactericidal against S. aureus and S. epidermidis. The mean maximal moxifloxacin concentrations were also much higher than the median MICs for other susceptible gram-positive pathogens and for all the gram-negative pathogens. 13 The results of our study show that moxifloxacin 0.5% is rapidly and extensively absorbed into the aqueous humor by the topical route. Both the mean C max and AUC 0-3h were numerically greater for the group dosed 4 times per day the day before surgery plus 4 drops at 15-minute intervals just prior to surgery than the group receiving only the 4-drop regimen just prior to surgery. The difference in AUC was statistically significant (P = 0.04). However, considering the extremely high C max :MIC ratios for susceptible S. aureus and S. epidermidis, both regimens should be effective for prophylaxis.
The moxifloxacin concentrations determined in our study are similar to those currently being reported from another investigation. 14 In that study, Vigamox drops were administered 3 times per day for 3 days plus 3 doses at 15-minute intervals just prior to cataract surgery. They reported that the mean concentration of moxifloxacin in the aqueous humor was 1.31 6 0.46 mg/mL. Our results were somewhat higher (1.74 6 0.66 mg/mL), possibly because our aqueous sampling scheme included the C max . Their study also demonstrated that the aqueous concentrations of moxifloxacin were about 2-fold higher than gatifloxacin, another fourth-generation fluoroquinolone (Zymar Ò ; 0.63 6 0.30 mg/mL) and about 9-fold higher than ciprofloxacin (Ciloxan Ò ; 0.15 6 0.11 mg/mL).
CONCLUSIONS
After topical administration of moxifloxacin 0.5% ophthalmic solution (Vigamox Ò ), moxifloxacin penetrates the cornea and is well absorbed into the aqueous humor. Concentrations in the aqueous humor were 25-to 35-fold higher than the median MICs recently determined for S. aureus and S. epidermidis isolates from patients with endophthalmitis. Maximal moxifloxacin concentrations were also higher than the median MICs for other susceptible gram-positive pathogens and for all gram-negative pathogens that cause endophthalmitis. No significant difference in C max was observed between dosing 4 drops at 15-minute intervals before surgery compared with 4 doses the day before surgery followed by 4 drops at 15-minute intervals before surgery. There was a statistical difference in AUC 0-3h favoring the latter regimen; however, the significance of this difference is not known. Because of moxifloxacin's excellent intraocular penetration and its high C max :MIC ratio relative to the bacterial isolates most commonly seen in endophthalmitis, moxifloxacin would be an appropriate choice for topical prophylaxis before intraocular surgical procedures.
